Neuroblastoma Research
Ongoing Research
Studies are assessing the safety and efficacy of the ALK inhibitor crizotinib in children with refractory and relapsed neuroblastoma and looking for ways to improve the response to crizotinib.
The presence of ALK on neuroblastoma cells, but not normal tissue cells, makes it a promising target for immunotherapeutic intervention.
New drugs are being identified for assessment in clinical trials that target specific genetic profiles in children with neuroblastoma.
Researchers are investigating how the genetic profiles of tumors from children with neuroblastoma are indicative of how aggressively they behave and are also working to identify potential avenues for targeted intervention.
CHD5, a gene located on the distal portion of the short arm of chromosome 1, may function as a tumor suppressor gene and contribute to the development of malignant neuroblastoma when deleted.
Researchers at the Center for Childhood Cancer Research are working to generate a series of position papers intended to detail the recommended best practices for pediatric cancer surveillance.
Researchers are assessing the use of an RNA-modified form of chimeric antigen receptor (CAR) T cells to treat refractory and relapsed neuroblastoma.
A clinical trial is currently underway through the COG to evaluate the safety and efficacy combining a Wee1 inhibitor AZD-1775 and Irinotecan as treatment for relapsed and refractory neuroblastoma and medulloblastoma.
Molecular profiling of tumors from patients with relapsed or refractory neuroblastoma may help determine more rational treatment options.
Inhibition of the TRK tyrosine kinase family has shown enduring response in clinical trials and efforts are underway to assess newer TRK inhibitors.
Researchers are currently enrolling patients for this Phase III trial assessing the addition of the radiopharmaceutical MIBG to standard care for high-risk neuroblastoma.
Investigators are examining the use of injectable alpha-emitting radionuclide MABG, a potent form of radiotherapy that specifically targets neuroblastoma cells.